Indian Council of Medical Research, National Institute of Epidemiology, Chennai, India. Email:
Department of Community Medicine, ESIC Medical College and PGIMSR, K.K. Nagar, Chennai, Tamil Nadu, India.
Prev Chronic Dis. 2022 Aug 25;19:E53. doi: 10.5888/pcd19.210228.
Pre-existing comorbid conditions in COVID-19 patients are risk factors for developing severe disease and death. We aimed to determine the association of chronic liver disease (CLD), a comorbid condition, with severity of disease and death among COVID-19 patients.
We searched for studies reporting COVID-19 outcomes among CLD and non-CLD patients in databases including Medline, EMBASE, ScienceDirect, Google Scholar, and Cochrane Library from inception of the pandemic until February 2022. Risk of bias assessment was conducted by using the Newcastle-Ottawa Scale for assessing the quality of nonrandomized studies in meta-analyses. We conducted a meta-analysis with a random-effects model and reported pooled odds ratios (ORs) with 95% CIs.
We included 40 studies with 908,032 participants. Most studies were conducted in China and the US. COVID-19 patients with CLD had significantly higher odds of having a severe form of COVID-19 (pooled OR = 2.44; 95% CI, 1.89-3.16) and death (pooled OR = 2.35; 95% CI, 1.85-3.00) when compared with COVID-19 patients without CLD.
The presence of CLD is significantly related to adverse clinical outcomes among COVID-19 patients in terms of severity and mortality. Clinicians should develop a comprehensive intervention plan to manage these high-risk patients and reduce COVID-19-related deaths.
COVID-19 患者的现有合并症是发生重症和死亡的危险因素。我们旨在确定慢性肝病（CLD）这一合并症与 COVID-19 患者疾病严重程度和死亡的关系。
我们在数据库中检索了从大流行开始到 2022 年 2 月期间报告 CLD 和非 CLD 患者 COVID-19 结局的研究，包括 Medline、EMBASE、ScienceDirect、Google Scholar 和 Cochrane Library。使用纽卡斯尔-渥太华量表（Newcastle-Ottawa Scale）评估非随机研究在荟萃分析中的质量。我们采用随机效应模型进行荟萃分析，并报告合并优势比（OR）及其 95%置信区间（CI）。
我们纳入了 40 项研究，共 908032 名参与者。大多数研究在中国和美国进行。与无 CLD 的 COVID-19 患者相比，CLD 患者 COVID-19 严重程度（合并 OR = 2.44；95% CI，1.89-3.16）和死亡（合并 OR = 2.35；95% CI，1.85-3.00）的可能性显著更高。
CLD 的存在与 COVID-19 患者的临床不良结局显著相关，包括严重程度和死亡率。临床医生应制定全面的干预计划，以管理这些高危患者并降低 COVID-19 相关死亡。
